TITLE

Growth hormone reserve in adult beta thalassemia patients

AUTHOR(S)
Guy Vidergor; Ada Goldfarb; Benjamin Glaser; Rivka Dresner-Pollak
PUB. DATE
February 2007
SOURCE
Endocrine (1355008X);Feb2007, Vol. 31 Issue 1, p33
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reduced serum insulin-like growth factor-1 (IGF-1) and hypogonadotrophic hypogonadism are common features of adult β-thalassemia, and warrant evaluation of the growth hormone (GH)-IGF-1 axis. The aim of this study was to determine GH reserve in β-thalassemia patients (9 females, 7 males, 15 major, 1 intermedia), age 29.3 ± 6.9 years, BMI 21.3 ± 1.9 kg/m2, and in 20 age, sex and BMI-matched healthy controls, using the GH-releasing hormone (GHRH)–arginine test. The associations between peak GH response and hormonal and biochemical indices were evaluated. Using BMI-related cut-off limits for peak GH response in the GHRH–arginine test, 4/16 β-thalassemia patients had peak GH lower than 11.5 μg/l, the cut-off limit suggested for lean subjects, and were diagnosed as GH deficient (GHD). Using 9 μg/l as the cut-off limit 2/16 patients were GHD. Reduced serum IGF-1 and IGFBP-3 were present in 69% and 19% of the patients, respectively. Peak GH did not correlate with serum IGF-1, TSH, and fT4 levels or gonadal status. Neither peak GH nor IGF-1 correlated with serum ferritin. Our findings suggest that GHD is present in up to a quarter of adult β-thalassemia patients. The clinical benefits of GH therapy need to be determined. GHD alone does not account for the high prevalence of reduced IGF-1 in adult β-thalassemia.
ACCESSION #
26845289

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics